Trade

Akums Drugs and Pharmaceuticals share price

Balanced risk
  • 26%Low risk
  • 26%Moderate risk
  • 26%Balanced risk
  • 26%High risk
  • 26%Extreme risk
  • ₹421.65(0.32%)
    December 5, 2025 15:28:16 PM IST
    • NSE
    • BSE
  • Vol : 86.26 K (NSE + BSE)
    Last 20 day avg : 242.05 K

Akums Drugs and Pharmaceuticals is trading 0.32% upper at Rs 421.65 as compared to its last closing price. Akums Drugs and Pharmaceuticals has been trading in the price range of 422.30 & 417.00. Akums Drugs and Pharmaceuticals has given -33.47% in this year & 2.58% in the last 5 days. There are 3 analysts who have initiated coverage on Akums Drugs and Pharmaceuticals. There are 2 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 40.78 Crores in its last quarter.Listed peers of Akums Drugs and Pharmaceuticals include Dr Reddy's Laboratories (-0.04%), Sun Pharmaceutical Industries (-0.75%), Cipla (-0.04%).The Mutual Fund holding in Akums Drugs and Pharmaceuticals was at 6.44% in 30 Sep 2025. The MF holding has decreased from the last quarter. The FII holding in Akums Drugs and Pharmaceuticals was at 2.27% in 30 Sep 2025. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Dec 06, 2025, 10:15 AM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.00
    Lower than industry
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    -
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    -
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
417.00
Highest
422.30
52 week range
Lowest
407.40
Highest
678.80
Akums Drugs and Pharmaceuticals News
Akums Drugs and Pharmaceuticals Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Dr Reddy's Laboratories
Bullish
1,276.55-0.041,06,330.4218.803.170.632.34
Sun Pharmaceutical Industries
Bullish
1,805.00-0.754,33,140.8537.946.040.880.50
Cipla
Neutral
1,520.55-0.041,22,825.6523.333.940.850.81
Torrent Pharmaceuticals
Bullish
3,773.70-0.741,27,661.9766.6416.920.8417.62
Divi's Laboratories
Bullish
6,468.25-0.041,73,113.6278.2711.470.460.01
Mutual Fund Ownership
View all
Groww Value Fund Regular Growth
1/5
  • Amount Invested (Cr.) 1.18
  • % of AUM 2.14
Franklin India Opportunities Fund Growth
NA
  • Amount Invested (Cr.) 110.92
  • % of AUM 1.62
Templeton India Value Fund Growth
3/5
  • Amount Invested (Cr.) 34.29
  • % of AUM 1.54
Tata Young Citizen [After 7 years]
NA
  • Amount Invested (Cr.) 5.43
  • % of AUM 1.48
Tata Young Citizen Fund [>3 years upto 7 years] Plan A
3/5
  • Amount Invested (Cr.) 5.43
  • % of AUM 1.48
Akums Drugs and Pharmaceuticals Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2025-11-13Quarterly Results
2025-08-08Quarterly Results
2025-05-26Audited Results
2025-02-06Quarterly Results
2024-11-09Quarterly Results
About the company Akums Drugs and Pharmaceuticals
  • IndustryBiotechnology & Drugs
  • ISININE09XN01023
  • BSE Code544222
  • NSE CodeAKUMS
Akums Drugs and Pharmaceuticals Limited is an India-based pharmaceutical contract development and manufacturing company. The Company offers a comprehensive range of pharmaceutical products and services in India and overseas. The Company’s segments include Contract Development and Manufacturing Operations (CDMO), Active Pharmaceutical Ingredient (API), Domestic Branded Formulations, International Branded Formulations, and Trade Generics. The CDMO segment is engaged in formulation research and development, preparation and regulatory filing of dossiers, manufacturing formulations on a contract basis, job work and testing services. The API segment is engaged in the manufacture and sale of key starting materials, Intermediate and API products. The Domestic Branded Formulations segment includes marketing of its branded formulations in the Indian market. The International Branded Formulations segment undertakes the marketing of its branded formulations in the global market.
  • Management Info
  • Sumeet SoodChief Financial Officer
  • Dharamvir MalikCompliance Officer, Company Secretary
  • Sandeep JainManaging Director, Executive Director
  • Sanjeev JainManaging Director, Executive Director
  • Sanjay SinhaWhole Time Director, President - Operations
Akums Drugs and Pharmaceuticals Share Price FAQs

Akums Drugs and Pharmaceuticals is trading at 421.65 as on Fri Dec 05 2025 09:58:16. This is 0.32% upper as compared to its previous closing price of 420.30.

The market capitalization of Akums Drugs and Pharmaceuticals is 6641.26 Cr as on Fri Dec 05 2025 09:58:16.

The average broker rating on Akums Drugs and Pharmaceuticals is Strong Buy. The breakup of analyst rating is given below -

  • 2 analysts have given a strong buy rating
  • 1 analysts have given a buy rating
  • 0.00 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 0.00 analysts have given a strong sell rating

The 52 wk high for Akums Drugs and Pharmaceuticals is 678.80 whereas the 52 wk low is 407.40

Akums Drugs and Pharmaceuticals can be analyzed on the following key metrics -

  • TTM P/E: 21.32
  • Sector P/E: -
  • Dividend Yield: 0.00%
  • D/E ratio: 0.03

Akums Drugs and Pharmaceuticals reported a net profit of 338.18 Cr in 2025.

The Mutual Fund Shareholding was 6.44% at the end of 30 Sep 2025.

Quick Links
EQUITY QUICK LINKS
Akums Drugs and Pharmaceuticals QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Business News/Market/Market Stats/  Akums Drugs and Pharmaceuticals share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.